Skip to main content

Table 4 Multivariable Cox proportional hazard model to identify factors associated with PFS in the overall population

From: Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

Multivariable Cox proportional hazard model (N = 319) Hazard ratio 95% confidence interval p-value
First diagnosed at an earlier stage vs. de novo MBC diagnosis 1.42a 1.09–1.85 0.009
Presence of liver metastases vs. No liver metastases 1.45b 1.10–1.93 0.009
Presence of bone metastases vs. No bone metastases 0.91c 0.69–1.20 0.509
Receipt of endocrine therapy vs. No endocrine therapy as part of first line treatment 0.70d 0.51–0.95 0.024
Negative vs. Positive HER2 status 0.91e 0.68–1.22 0.531
Positive vs. Negative HR status 1.01f 0.74–1.37 0.970
Age at MBC diagnosis (years) 1.00g 0.99–1.01 0.953
Time from MBC diagnosis to first line treatment (months) 0.97h 0.93–1.01 0.154
  1. aAdjusted for presence of liver and bone metastases, receipt of endocrine therapy in the first line setting, HR and HER2 status, age at MBC diagnosis, and MBC duration at first line treatment onset
  2. bAdjusted for diagnosis of MBC de novo, presence of bone metastases, receipt of endocrine therapy in the first line setting, HR and HER2 status, age at MBC diagnosis, and MBC duration at first line treatment onset
  3. cAdjusted for diagnosis of MBC de novo, presence of liver metastases, receipt of endocrine therapy in the first line setting, HR and HER2 status, age at MBC diagnosis, and MBC duration at first line treatment onset
  4. dAdjusted for diagnosis of MBC de novo, presence of liver and bone metastases, HR and HER2 status, age at MBC diagnosis, and MBC duration at first line treatment onset
  5. e Adjusted for diagnosis of MBC de novo, presence of liver and bone metastases, receipt of endocrine therapy in the first line setting, HR status, age at MBC diagnosis, and MBC duration at first line treatment onset
  6. fAdjusted for diagnosis of MBC de novo, presence of liver and bone metastases, receipt of endocrine therapy in the first line setting, HER2 status, age at MBC diagnosis, and MBC duration at first line treatment onset
  7. gAdjusted for diagnosis of MBC de novo, presence of liver and bone metastases, receipt of endocrine therapy in the first line setting, HR and HER2 status, and MBC duration at first line treatment onset
  8. hAdjusted for diagnosis of MBC de novo, presence of liver and bone metastases, receipt of endocrine therapy in the first line setting, HR and HER2 status, and age at MBC diagnosis